Antiviral agent 35 (compound 4d) serves as a potent orally active inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, and apoptosis, along with the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, displaying a CC50 greater than 800 μM, and possesses anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM [1].

抗病毒药物35（化合物4d）以25 μM及50 μM的浓度，在24至72小时内有效抑制MDCK细胞中的流感病毒复制[1]。

抗病毒药物35（化合物4d）（剂量分别为25mg/kg/d、50mg/kg/d、100mg/kg/d；通过灌胃；2-6天）在H1N1感染后第2、4、6天降低小鼠肺部炎症[1]。